XMD17-109 - ERK 抑制劑 - 生命科學(xué)試劑 - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEXMD17-109Cat. No.: HY-15665CAS No.: 1435488-37-1分式: CHNO分量: 638.8作靶點(diǎn): ERK作通路: MAPK/ERK Pathway; Stem Cell/Wnt儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 100 mg/mL (156.54 mM)* means sol

2、uble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.5654 mL 7.8272 mL 15.6544 mL5 mM 0.3131 mL 1.5654 mL 3.1309 mL10 mM 0.1565 mL 0.7827 mL 1.5654 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?，配制前?qǐng)先配制澄清的儲(chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)

3、天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (3.91 mM); Clear solution2. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (3.91 mM); Clear solution3. 請(qǐng)依序添加每種溶劑： 10% DMSO 90% corn oil1/3 Master of Sm

4、all Molecules 您邊的抑制劑師www.MedChemESolubility: 2.5 mg/mL (3.91 mM); Clear solutionBIOLOGICAL ACTIVITY物活性 XMD17-109種特異性的 ERK-5 抑制劑，IC50 值為 162 nM。IC50 & Target ERK5 LRRK2G2019S162 nM (IC50) 339 nM (IC50)體外研究 XMD17-109 (Compound 26) inhibits ERK5 biochemically with an IC50 of 0.162 0.006 M, and blockspi

5、dermal growth factor induced ERK5 autophosphorylation with an EC50 of 0.09 0.03 M in cells. XMD17-109 also inhibits LRRK2G2019S with an IC50 of 339 nM 1. XMD17-109 demonstrats low nanomolarcellular activity judged by the significant dose-dependent reduction of mobility shifted phosphorylated ERK5ban

6、ds from sorbitol stimulated cells. XMD17-109 completely inhibits the ERK5-mediated AP1 transcriptionalactivity at 30 M and has an EC50 of 4.2 M 2.PROTOCOLCell Assay 2 HeLa cells are maintained in DMEM supplemented with 10% FBS, 2 mM l-glutamine, 50 U/mL penicillin G,and 50 g/mL streptomycin. Before

7、use HeLa cells are serum starved for 16 h in DMEM supplemented with 2mM l-glutamine, 50 U/mL penicillin G, and 50 g/mL streptomycin. HeLa cells are then incubated with ERK5-IN-1 at the indicated concentrations for 1 h prior to stimulation with 0.5mol/Lsorbitol for 30 min. Cells arelysed in Triton ly

8、sis buffer (50 mM Tris-HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate,50 mM sodium fluoride, 1 mM sodium pyrophosphate, 0.27mol/Lsucrose, 1 M microcystin-LR, 1% (v/v)Triton X-100, 0.1% (v/v) 2-mercaptoethanol) and 20 g of protein loaded per well. Samples are run on 8%polyacrylamide gel

9、s using standard methods. Proteins are transferred onto nitrocellulose membranes andspecific proteins detected by immunoblotting.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶(hù)使本產(chǎn)品發(fā)表的科研獻(xiàn) Sci Signal. 2015 Aug 25;8(391):ra86. Oncotarget. 2016 Jun 7;7(23

10、):34322-40.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Deng X, et al. Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzoepyrimido-5,4-bdiazepine-6(11H)-ones. Eur J Med Chem. 2013;70:758-67.2. Elkins, Jonathan M., et al. X-ray Cryst

11、al Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor. Journal of Medicinal Chemistry(2013), 56(11), 4413-4421.2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE3. Wilhelmsen K, et al. Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation. Sci Signal. 2015 Aug25;8(391):ra86.McePdfHeightCaution: Product has not